Pharmaceutical and life sciences companies have won admirers for innovating quickly in a very tough situation this year. With unprecedented pressure on regulators and pharmaceutical organisations to bring COVID-19 treatments to market as soon as possible, we should expect quality functions within pharma companies to come under a brighter spotlight.
Based on our experience transforming quality functions with leading pharmaceutical companies, we see enormous potential for quality to act as a value creator across an organisation’s operations. Here we assess the characteristics of high‑performance quality functions and highlight areas of particular interest for the months and years ahead.
Click here to read the article.
Why Private Equity Works in Value-Based Primary Care
February 2, 2026
Private equity’s influence in value‑based primary care is widely debated, but new evidence shows a different reality. This analysis gives healthcare leaders clarity on where disciplined capital strengthens care models, and where it doesn’t.
The State of Transformation for U.S. Healthcare Providers
January 26, 2026
Market dynamics for health systems are shifting. The most significant driver is the federal Medicaid mandate, which expired at the end of December 2025 and is now pending legislation. This uncertainty is prompting health system leaders to rethink strategy and operations. In this context, we’ll share how other health systems are responding and what these changes mean for organizations like yours.
Strategic Agility for Healthcare Leaders: Building Resilience Amid Disruption
January 12, 2026
The healthcare industry stands at a critical crossroads, grappling with an era of profound disruption and uncertainty. Over the past two decades, the pace of change has accelerated dramatically, reshaping the competitive landscape and challenging the ability of all stakeholders to adapt.
Provider-Sponsored Health Plans: Bridge or Anchor?
December 17, 2025
Provider-sponsored health plans are no longer neutral—they either create enterprise value or drain capital. This analysis gives CFOs and CEOs a clear framework to decide whether to scale, partner, restructure, or exit.
